David I Bernstein1, Lisa Jackson2, Shital M Patel3, Hana M El Sahly3, Paul Spearman4, Nadine Rouphael5, Thomas L Rudge6, Heather Hill7, Johannes B Goll7. 1. Cincinnati Children's Hospital Medical Center, University of Cincinnati, 3333 Burnet Ave., Cincinnati, OH 45229, USA. Electronic address: david.bernstein@cchmc.org. 2. Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA. 3. Baylor College of Medicine, Houston, TX, USA. 4. Emory University School of Medicine, Atlanta, GA, USA. 5. Hope Clinic of the Emory Vaccine Center, Atlanta, GA, USA. 6. Battelle Memorial Institute, Columbus, OH, USA. 7. The EMMES Corporation, Rockville, MD, USA.
Abstract
BACKGROUND: Strategies to implement post exposure prophylaxis (PEP) in case of an anthrax bioterror event are needed. To increase the number of doses of vaccine available we evaluated reducing the amount of vaccine administered at each of the vaccinations, and reducing the number of doses administered. METHODS:Healthy male and non-pregnant female subjects between the ages of 18 and 65 were enrolled and randomized 1:1:1:1 to one of four study arms to receive 0.5 mL (standard dose) of vaccine subcutaneously (SQ) at: (A) days 0, 14; (B) days 0 and 28; (C) days 0, 14, and 28; or (D) 0.25 mL at days 0, 14, and 28. A booster was provided on day 180. Safety was assessed after each dose. Blood was obtained on days 0, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 84, 100, 180, and 201 and both Toxin Neutralizing antibody and anti-PA IgG antibody measured. RESULTS: Almost all subjects developed some local reactions with 46-64% reported to be of moderate severity and 3.3% severe during the primary series. Vaccine groups that included a day 14 dose induced a ≥ 4 fold antibody rise in more subjects on days 21, 28, and 35 than the arm without a day 14 dose. However, schedules with a full day 28 dose induced higher peak levels of antibody that persisted longer. The half dose regimen did not induce antibody as well as the full dose study arms. CONCLUSION: Depending on the extent of the outbreak, effectiveness of antibiotics and availability of vaccine, the full dose 0, 28 or 0, 14, 28 schedules may have advantages.
RCT Entities:
BACKGROUND: Strategies to implement post exposure prophylaxis (PEP) in case of an anthrax bioterror event are needed. To increase the number of doses of vaccine available we evaluated reducing the amount of vaccine administered at each of the vaccinations, and reducing the number of doses administered. METHODS: Healthy male and non-pregnant female subjects between the ages of 18 and 65 were enrolled and randomized 1:1:1:1 to one of four study arms to receive 0.5 mL (standard dose) of vaccine subcutaneously (SQ) at: (A) days 0, 14; (B) days 0 and 28; (C) days 0, 14, and 28; or (D) 0.25 mL at days 0, 14, and 28. A booster was provided on day 180. Safety was assessed after each dose. Blood was obtained on days 0, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 84, 100, 180, and 201 and both Toxin Neutralizing antibody and anti-PA IgG antibody measured. RESULTS: Almost all subjects developed some local reactions with 46-64% reported to be of moderate severity and 3.3% severe during the primary series. Vaccine groups that included a day 14 dose induced a ≥ 4 fold antibody rise in more subjects on days 21, 28, and 35 than the arm without a day 14 dose. However, schedules with a full day 28 dose induced higher peak levels of antibody that persisted longer. The half dose regimen did not induce antibody as well as the full dose study arms. CONCLUSION: Depending on the extent of the outbreak, effectiveness of antibiotics and availability of vaccine, the full dose 0, 28 or 0, 14, 28 schedules may have advantages.
Authors: P R Pittman; J A Mangiafico; C A Rossi; T L Cannon; P H Gibbs; G W Parker; A M Friedlander Journal: Vaccine Date: 2000-09-15 Impact factor: 3.641
Authors: Phillip R Pittman; Gina Kim-Ahn; Dominique Y Pifat; Kevin Coonan; Paul Gibbs; Steve Little; Judith G Pace-Templeton; Robert Myers; Gerald W Parker; Arthur M Friedlander Journal: Vaccine Date: 2002-01-31 Impact factor: 3.641
Authors: L Mark Kao; Karen Bush; Roy Barnewall; James Estep; Frederic W Thalacker; Pamela H Olson; George L Drusano; Neil Minton; Shuchean Chien; Alex Hemeryck; Michael F Kelley Journal: Antimicrob Agents Chemother Date: 2006-11 Impact factor: 5.191
Authors: Darrell E Singer; Rachel Schneerson; Christian T Bautista; Mark V Rubertone; John B Robbins; David N Taylor Journal: Vaccine Date: 2007-12-26 Impact factor: 3.641
Authors: Nina Marano; Brian D Plikaytis; Stacey W Martin; Charles Rose; Vera A Semenova; Sandra K Martin; Alison E Freeman; Han Li; Mark J Mulligan; Scott D Parker; Janiine Babcock; Wendy Keitel; Hana El Sahly; Gregory A Poland; Robert M Jacobson; Harry L Keyserling; Stephen D Soroka; Sarah P Fox; John L Stamper; Michael M McNeil; Bradley A Perkins; Nancy Messonnier; Conrad P Quinn Journal: JAMA Date: 2008-10-01 Impact factor: 56.272
Authors: Phillip R Pittman; Sarah L Norris; Julio G Barrera Oro; David Bedwell; Timothy L Cannon; Kelly T McKee Journal: Vaccine Date: 2006-02-09 Impact factor: 3.641
Authors: Han Li; Stephen D Soroka; Thomas H Taylor; Karen L Stamey; Kelly Wallace Stinson; Alison E Freeman; Darbi R Abramson; Rita Desai; Li X Cronin; J Wade Oxford; Joseph Caba; Cynthia Pleatman; Sonal Pathak; Daniel S Schmidt; Vera A Semenova; Sandra K Martin; Patricia P Wilkins; Conrad P Quinn Journal: J Immunol Methods Date: 2008-02-08 Impact factor: 2.303
Authors: Jennifer G Wright; Brian D Plikaytis; Charles E Rose; Scott D Parker; Janiine Babcock; Wendy Keitel; Hana El Sahly; Gregory A Poland; Robert M Jacobson; Harry L Keyserling; Vera A Semenova; Han Li; Jarad Schiffer; Hanan Dababneh; Sandra K Martin; Stacey W Martin; Nina Marano; Nancy E Messonnier; Conrad P Quinn Journal: Vaccine Date: 2013-12-25 Impact factor: 4.169
Authors: G S Sivko; G V Stark; K P Tordoff; K L Taylor; E Glaze; M VanRaden; J M Schiffer; J A Hewitt; C P Quinn; E O Nuzum Journal: Vaccine Date: 2016-05-04 Impact factor: 3.641
Authors: G V Stark; G S Sivko; M VanRaden; J Schiffer; K L Taylor; J A Hewitt; C P Quinn; E O Nuzum Journal: Vaccine Date: 2016-08-22 Impact factor: 3.641